The potential risk is of thyroid cancer which is already clearly identified in the drug insert.
Semaglutide, and other drugs in the same category (glucagon-like peptide GLP-1 receptor antagonists), have been available in the market for over a decade. This is according to Andersen-Lange, Novo Nordisk’s products.
Additionally, the safety data gathered from clinical trials and post marketing surveillance have not shown any conclusive evidence linking them to thyroid cancer.
The potential risk is of thyroid cancer which is already clearly identified in the drug insert.
Semaglutide, and other drugs in the same category (glucagon-like peptide GLP-1 receptor antagonists), have been available in the market for over a decade. This is according to Andersen-Lange, Novo Nordisk’s products.
Additionally, the safety data gathered from clinical trials and post marketing surveillance have not shown any conclusive evidence linking them to thyroid cancer.